Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues
Adia Med reported interim safety results from the first cohort of its randomized Phase 1/2 autism study (NCT07304440), with no serious adverse events in either arm and nothing requiring IRB reporting. The only treatment-related findings were two mild rashes attributed to the topical glutathione spray, both of which resolved without medical treatment after the spray was discontinued. Enrollment continues toward a target of approximately 100 children, with efficacy to be assessed via parent- and therapist-reported ATEC scores.
Key figures
- Drug Name
- AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione
- Phase Of Trial
- Phase 1/2
- Cohort age range
- 3 to 12
- Planned enrollment
- approximately 100 children
- Serious adverse events
- 0
- Treatment related findings
- two mild rashes attributed to topical glutathione spray, both resolved
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.